Carl Zeiss Meditec AG (XBUL:AFX) Cyclically Adjusted Revenue per Share: лв22.56 (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

XBUL:AFX Carl Zeiss Meditec AG XBUL:AFX
70 GF Score
Price лв42.34
GF Value лв108.10
! 4 Warning Signs
View Full Analysis

What is Carl Zeiss Meditec AG Cyclically Adjusted Revenue per Share?

Carl Zeiss Meditec AG XBUL:AFX 70 Cyclically Adjusted Revenue per Share is лв22.56 as of Dec. 2025. GuruFocus rates XBUL:AFX with a GF Score™ of 70/100 and a GF Value™ of лв108.10. The stock has 4 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Carl Zeiss Meditec AG's adjusted revenue per share for the three months ended in Dec. 2025 was лв11.500. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is лв22.56 for the trailing ten years ended in Dec. 2025.

During the past 12 months, Carl Zeiss Meditec AG's average Cyclically Adjusted Revenue Growth Rate was 6.20% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was 8.00% per year. During the past 5 years, the average Cyclically Adjusted Revenue Growth Rate was 9.80% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of Carl Zeiss Meditec AG was 11.40% per year. The lowest was 5.30% per year. And the median was 8.65% per year.

As of today (2026-07-29), Carl Zeiss Meditec AG's current stock price is лв42.34. Carl Zeiss Meditec AG's Cyclically Adjusted Revenue per Share for the quarter that ended in Dec. 2025 was лв22.56. Carl Zeiss Meditec AG's Cyclically Adjusted PS Ratio of today is 1.88.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Carl Zeiss Meditec AG was 13.68. The lowest was 1.10. And the median was 6.23.


Carl Zeiss Meditec AG  (XBUL:AFX) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Carl Zeiss Meditec AG's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=42.34/22.56
=1.88

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Carl Zeiss Meditec AG was 13.68. The lowest was 1.10. And the median was 6.23.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Carl Zeiss Meditec AG Cyclically Adjusted Revenue per Share Related Terms


Carl Zeiss Meditec AG Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for Carl Zeiss Meditec AG's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Carl Zeiss Meditec AG Cyclically Adjusted Revenue per Share Chart

Carl Zeiss Meditec AG Annual Data
Trend Sep16 Sep17 Sep18 Sep19 Sep20 Sep21 Sep22 Sep23 Sep24 Sep25
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 20.84

Carl Zeiss Meditec AG Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 18.51 20.00 20.84 22.56

XBUL:AFX vs ISRG, BDX, MDLN: Cyclically Adjusted Revenue per Share Comparison

For the Medical Instruments & Supplies subindustry, Carl Zeiss Meditec AG's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Carl Zeiss Meditec AG Cyclically Adjusted PS Ratio vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Carl Zeiss Meditec AG's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Carl Zeiss Meditec AG's Cyclically Adjusted PS Ratio falls into.


XBUL:AFX
70GF Score
Carl Zeiss Meditec AG XBUL:AFX
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Carl Zeiss Meditec AG Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Carl Zeiss Meditec AG's adjusted Revenue per Share data for the three months ended in Dec. 2025 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Dec. 2025 (Change)*Current CPI (Dec. 2025)
=11.5/129.3606*129.3606
=11.500

Current CPI (Dec. 2025) = 129.3606.

Carl Zeiss Meditec AG Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201603 6.511 100.017 8.421
201606 6.036 100.717 7.753
201609 6.966 101.017 8.921
201612 6.238 101.217 7.972
201703 6.912 101.417 8.816
201706 6.021 102.117 7.627
201709 7.391 102.717 9.308
201712 6.726 102.617 8.479
201803 7.594 102.917 9.545
201806 7.032 104.017 8.745
201809 7.835 104.718 9.679
201812 7.050 104.217 8.751
201903 7.486 104.217 9.292
201906 7.852 105.718 9.608
201909 9.076 106.018 11.074
201912 7.819 105.818 9.559
202003 7.312 105.718 8.947
202006 5.462 106.618 6.627
202009 8.435 105.818 10.312
202012 8.657 105.518 10.613
202103 9.151 107.518 11.010
202106 10.099 108.486 12.042
202109 10.091 109.435 11.928
202112 8.822 110.384 10.339
202203 9.375 113.968 10.641
202206 9.704 115.760 10.844
202209 10.802 118.818 11.760
202212 9.563 119.345 10.366
202303 10.318 122.402 10.905
202306 11.141 123.140 11.704
202309 11.947 124.195 12.444
202312 9.991 123.773 10.442
202403 9.861 125.038 10.202
202406 11.112 125.882 11.419
202409 12.668 126.198 12.985
202412 10.114 127.041 10.299
202503 11.928 127.779 12.076
202506 12.291 128.412 12.382
202509 14.507 129.255 14.519
202512 11.500 129.361 11.500

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of лв22.56 mean?
Carl Zeiss Meditec AG (XBUL:AFX) has a Cyclically Adjusted Revenue per Share of лв22.56 as of Dec. 2025. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Carl Zeiss Meditec AG and its competitors.
Is Carl Zeiss Meditec AG's Cyclically Adjusted Revenue per Share too high?
Carl Zeiss Meditec AG's current Cyclically Adjusted Revenue per Share is лв22.56. Overall, Carl Zeiss Meditec AG has a GF Score™ of 70/100, reflecting its overall financial health beyond just this single metric.
How does Carl Zeiss Meditec AG's Cyclically Adjusted Revenue per Share compare to ISRG and BDX?
Carl Zeiss Meditec AG's Cyclically Adjusted Revenue per Share of лв22.56 can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Medical Devices & Instruments company?
A good Cyclically Adjusted Revenue per Share depends on the Medical Devices & Instruments industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Carl Zeiss Meditec AG and its competitors. Carl Zeiss Meditec AG's current Cyclically Adjusted Revenue per Share is лв22.56. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Carl Zeiss Meditec AG stock overvalued right now?
Carl Zeiss Meditec AG (XBUL:AFX) has a current Cyclically Adjusted Revenue per Share of лв22.56. The stock's GF Value™ is лв108.10, compared to a current price of лв42.34 — trading 60.8% below its estimated fair value. The current Cyclically Adjusted Revenue per Share is лв22.56. Carl Zeiss Meditec AG's overall GF Score™ is 70/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For Carl Zeiss Meditec AG (XBUL:AFX), the current Cyclically Adjusted Revenue per Share is лв22.56 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Carl Zeiss Meditec AG (XBUL:AFX) Overvalued in 2026?

Based on GuruFocus' analysis, Carl Zeiss Meditec AG stock appears to be undervalued. The current stock price of лв42.34 is trading 60.8% below its estimated GF Value™ of лв108.10.

Key valuation signals for XBUL:AFX:

  • Cyclically Adjusted Revenue per Share: лв22.56
  • GF Value™: лв108.10 vs. price of лв42.34 (60.8% below fair value)
  • GF Score™: 70/100 with 4 warning signs

No single metric tells the full story. See the XBUL:AFX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Carl Zeiss Meditec AG Business Description

Address Goschwitzer Strasse 51-52, Jena, TH, DEU, 07745
Carl Zeiss Meditec is one of the largest visioncare technology companies in the world, and it operates in two segments: ophthalmic devices and microsurgery. OPT, which made up about 75% of sales in 2025, includes refractive lasers, surgical ophthalmic devices, equipment for ophthalmic diagnostics, as well as a portfolio of intraocular lenses and disposable medical instruments. With a low-teens share of the market, Zeiss is the second-largest player in the space. MCS is composed of implants, surgical instruments, and visualization devices used during neurosurgery, spine surgery, and otolaryngology surgery. With over 60% market share, Zeiss is the clear leader in the microsurgery space.
70GF Score

Get the complete analysis for XBUL:AFX

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

лв42.34
Price
лв108.10
GF Value